Novartis "neutral"

17.01.07 - J.P. Morgan Securities

LONDON, January 17 (newratings.com) - Analysts at JP Morgan maintain their "neutral" rating on Novartis (NOT). The target price is set to CHF74.

In a research note published this morning, the analysts mention that the company is expected to post robust 4Q results on January 18, with the Glivec, Lotrel and Diovan franchises reporting robust sales. Novartis? underlying EBIT growth for the quarter is expected to be lower than its reported growth, the analysts say. Novartis? comps are expected to continue to be tough going forward due to the company?s recent acquisitions, JP Morgan adds.